Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2005

01-01-2005 | Article

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

Authors: G. D. Tan, B. A. Fielding, J. M. Currie, S. M. Humphreys, M. Désage, K. N. Frayn, M. Laville, H. Vidal, F. Karpe

Published in: Diabetologia | Issue 1/2005

Login to get access

Abstract

Aims/hypothesis

We investigated the effects of rosiglitazone on NEFA and triglyceride metabolism in type 2 diabetes.

Methods

In a double-blind, placebo-controlled, cross-over study of rosiglitazone in diet-treated type 2 diabetic subjects, we measured arteriovenous differences and tissue blood flow in forearm muscle and subcutaneous abdominal adipose tissue, used stable isotope techniques, and analysed gene expression. Responses to a mixed meal containing [1,1,1-13C]tripalmitin were assessed.

Results

Rosiglitazone induced insulin sensitisation without altering fasting NEFA concentrations (−6.6%, p=0.16). Postprandial NEFA concentrations were lowered by rosiglitazone compared with placebo (−21%, p=0.04). Adipose tissue NEFA release was not decreased in the fasting state by rosiglitazone treatment (+24%, p=0.17) and was associated with an increased fasting hormone-sensitive lipase rate of action (+118%, p=0.01). Postprandial triglyceride concentrations were decreased by rosiglitazone treatment (−26%, p<0.01) despite unchanged fasting concentrations. Rosiglitazone did not change concentrations of triglyceride-rich lipoprotein remnants. Adipose tissue blood flow increased with rosiglitazone (+32%, p=0.03). Postprandial triglyceride [13C]palmitic acid concentrations were unchanged, whilst NEFA [13C]palmitic acid concentrations were decreased (p=0.04). In muscle, hexokinase II mRNA expression was increased by rosiglitazone (+166%, p=0.001) whilst the expression of genes involved in insulin signalling was unchanged. Adipose tissue expression of FABP4, LPL and FAT/CD36 was increased.

Conclusions/interpretation

Rosiglitazone decreases postprandial NEFA and triglyceride concentrations. This may represent decreased spillover of NEFAs from adipose tissue depots. Decreased delivery of NEFAs to the liver may lead to lowered postprandial triglyceride concentrations. Upregulation of hexokinase II expression in muscle may contribute to insulin sensitisation by rosiglitazone.
Literature
1.
2.
Way JM, Harrington WW, Brown KK et al (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269–1277CrossRefPubMed
3.
Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789CrossRefPubMed
4.
Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3–10PubMed
5.
Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265–294CrossRef
6.
Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI (2000) Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827–831PubMed
7.
Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA (2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122–1128CrossRef
8.
Tan GD, Debard C, Tiraby C et al (2003) A “futile cycle” induced by thiazolidinediones in human adipose tissue? Nat Med 9:811–812CrossRef
9.
Finegood DT, McArthur MD, Kojwang D et al (2001) Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021–1029PubMed
10.
Zhou YT, Grayburn P, Karim A et al (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784–1789
11.
Maggs DG, Buchanan TA, Burant CF et al (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176–185PubMed
12.
Mayerson AB, Hundal RS, Dufour S et al (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797–802PubMed
13.
Hällsten K, Virtanen KA, Lönnqvist F et al (2002) Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479–3485
14.
Nolan JJ, Jones NP, Patwardhan R, Deacon LF (2000) Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17:287–294CrossRef
15.
King AB (2000) A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23:557
16.
Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947–952CrossRef
17.
Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278–284CrossRef
18.
Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17:40–47CrossRef
19.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695–1702CrossRef
20.
Miyazaki Y, Mahankali A, Matsuda M et al (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719
21.
Bajaj M, Suraamornkul S, Pratipanawatr T et al (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364–1370PubMed
22.
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605–1611
23.
Sakamoto J, Kimura H, Moriyama S et al (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704–711
24.
Vu-Dac N, Schoonjans K, Kosykh V et al (1995) Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741–750
25.
Karpe F (2002) Postprandial lipemia-effect of lipid-lowering drugs. Atheroscler Suppl 3:41–46CrossRef
26.
Ghazzi MN, Perez JE, Antonucci TK et al (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46:433–439PubMed
27.
Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM (1997) Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20:188–193PubMed
28.
Sunayama S, Watanabe Y, Ohmura H et al (1999) Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 146:187–193CrossRef
29.
Shirai K, Itoh Y, Sasaki H et al (1999) The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35–41CrossRef
30.
Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193–203
31.
Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818–1820CrossRefPubMed
32.
Kobayashi J, Nagashima I, Hikita M et al (1999) Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47:433–439CrossRef
33.
Ranganathan S, Kern PA (1998) Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. J Biol Chem 273:26117–26122CrossRef
34.
Rieusset J, Auwerx J, Vidal H (1999) Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265–271CrossRef
35.
McTernan PG, Harte AL, Anderson LA et al (2002) Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 51:1493–1498
36.
Frayn KN, Coppack SW (2001) Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269–279
37.
Frayn KN, Coppack SW, Humphreys SM, Whyte PL (1989) Metabolic characteristics of human adipose tissue in vivo. Clin Sci (Lond) 76:509–516
38.
Larsen OA, Lassen NA, Quaade F (1966) Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 66:337–345
39.
Rådegran G (1999) Limb and skeletal muscle blood flow measurements at rest and during exercise in human subjects. Proc Nutr Soc 58:887–898
40.
Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN (2002) Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51:2684–2690PubMed
41.
Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A (2001) Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17–21
42.
Auboeuf D, Vidal H (1997) The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. Anal Biochem 245:141–148CrossRef
43.
Evans K, Clark ML, Frayn KN (1999) Effects of an oral and intravenous fat load on adipose tissue and forearm lipid metabolism. Am J Physiol 276:E241–E248
44.
Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192PubMed
45.
Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN (1996) Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 91:679–683
46.
Jansson PA, Larsson A, Lönnroth PN (1998) Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 28:813–818CrossRef
47.
Issekutz B Jr, Bortz WM, Miller HI, Paul P (1967) Turnover rate of plasma FFA in humans and in dogs. Metabolism 16:1001–1009CrossRef
48.
Bonadonna RC, Groop LC, Zych K, Shank M, DeFronzo RA (1990) Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 259:E736–E750
49.
Miyazaki Y, Glass L, Triplitt C et al (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210–2219CrossRef
50.
Auboeuf D, Rieusset J, Fajas L et al (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319–1327PubMed
51.
Guo Z, Hensrud DD, Johnson CM, Jensen MD (1999) Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 48:1586–1592.PubMed
52.
Kelly IE, Han TS, Walsh K, Lean ME (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288–293
53.
Virtanen KA, Hällsten K, Parkkola R et al (2003) Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283–290
54.
Frayn KN, Coppack SW, Fielding BA, Humphreys SM (1995) Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Adv Enzyme Regul 35:163–178CrossRef
55.
Tan KC, Tso AW, Tam SC, Pang RW, Lam KS (2002) Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 19:944–948CrossRef
56.
Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW (1994) Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43:293–298CrossRef
57.
Damci T, Yalin S, Balci H et al (2004) Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 27:1077–1080
58.
Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y (2003) PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52:291–299
59.
Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Invest 113:1582–1588CrossRef
60.
Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G (1995) Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158–166
61.
Malmstrom R, Packard CJ, Watson TD et al (1997) Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454–1464
62.
Lewis GF, Uffelman KD, Szeto LW, Steiner G (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42:833–842
63.
Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN (1998) Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 28:1024–1031
64.
Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN (2002) Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 51:2467–2473
65.
Campbell PJ, Carlson MG, Hill JO, Nurjhan N (1992) Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification. Am J Physiol 263:E1063–E1069
66.
Zierath JR, Ryder JW, Doebber T et al (1998) Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology 139:5034–5041CrossRef
67.
Kim YB, Ciaraldi TP, Kong A et al (2002) Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51:443–448
68.
Meyer MM, Levin K, Grimmsmann T et al (2002) Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 51:2691–2697
69.
Cline GW, Petersen KF, Krssak M et al (1999) Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240–246CrossRef
70.
Kelley DE, Mintun MA, Watkins SC et al (1996) The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705–2713
71.
Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248–257CrossRef
72.
Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O (1995) Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96:2639–2645
73.
Pendergrass M, Koval J, Vogt C et al (1998) Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387–394
74.
Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM (1998) Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107–1113
75.
Ducluzeau PH, Perretti N, Laville M et al (2001) Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50:1134–1142PubMed
76.
Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272:28210–28217CrossRef
Metadata
Title
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes
Authors
G. D. Tan
B. A. Fielding
J. M. Currie
S. M. Humphreys
M. Désage
K. N. Frayn
M. Laville
H. Vidal
F. Karpe
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1619-9

Other articles of this Issue 1/2005

Diabetologia 1/2005 Go to the issue

Article

Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity

Article

C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells

Article

Hormone-sensitive lipase is reduced in the adipose tissue of patients with type 2 diabetes mellitus: influence of IL-6 infusion

EASD

EASD News Section 1/2005

Article

Leisure time physical activity and the risk of type 2 diabetes in men and women from the general population

Article

Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits